We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > infigratinib

News List

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results PhamaSources.com
December 10, 2021
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma americanpharmaceuticalreview
June 04, 2021
The FDA granted accelerated approval to infigratinib, a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other ...